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Simon Lovestone discusses recent progress in the
development of molecular biomarkers for the
diagnosis and prognosis of Alzheimer’s disease.real difficulty is in identifying prodromal or even pre-Introduction
Simon Lovestone (Figure 1) is Professor of Translational
Neuroscience at the University of Oxford and Lead
for the NIHR Translational Research Collaboration in
Dementia, a network of experimental medicine centers
in the UK. He is a leading name in the research field of
blood biomarkers for Alzheimer’s disease. In this Q&A,
he shares with us his vision on the state of the art of the
field and on what will be required in the future.
What is the standard for diagnosis of Alzheimer’s
disease currently?
The standard today is to diagnose dementia according to
clinical criteria, for the most part using defined oper-
ational criteria, and with, for example, imaging used pri-
marily to exclude other diseases. Diagnosis of Alzheimer’s
disease (AD) and other dementias is actually reasonably
effective and accurate, and this has been demonstrated in
several studies, most of which concur on this point [1].
In fact, some years ago, we examined how accurate the
diagnostic process was, when performed by trained non-
medical researchers, using a standardized assessment
process. When tested against post-mortem follow-up
diagnosis, using such an assessment process, combined
with a computerized algorithm, had a positive predictive
value of at least 95% [2]. However, there are three ca-
veats to this. First, AD is by far and away the most com-
mon of the dementias and so, in any cohort, the positive
predictive value will be high for almost any diagnostic
process. Second, all diagnostic processes have an under-
lying assumption that dementias are categorical disor-
ders (Alzheimer’s, vascular dementias, fronto-temporalCorrespondence: simon.lovestone@psych.ox.ac.uk
Department of Psychiatry, University of Oxford, Warneford Hospital,
Oxford OX3 7JX, UK
© 2014 Lovestone; licensee BioMed Central Lt
12 months following its publication. After this
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.dementias, and so on) whereas, in fact, it would be more
accurate to think of them as syndromes emerging from
a continuum or spectrum of overlapping pathologies.
Third, all these comments about diagnostic accuracy
only apply when considering established dementia; the
clinical disease accurately. It is known that the disease
process starts a decade or more before the full dementia
syndrome is established. Especially when we want to do
clinical trials earlier, identifying people in these pre-
dementia states is really important but, today, really
difficult.Is the current approach used for diagnosis of
Alzheimer’s disease desirable?
Clearly this diagnostic approach - diagnosing disease up
to 10 years after onset and only when the symptoms are
so severe as to be obvious, and making categorical diag-
noses when we know there is usually a mixture or
spectrum of pathologies - is not desirable and is now in-
creasingly outdated. In fact, it is worse than that. Not
only is the diagnostic approach no longer adequate for
established dementia but, also, doctors are increasingly
being approached by people in the pre-dementia stages.
Here, the usual practice, at least in the UK, is to perform
an assessment of cognition and, if the patient does not
have full dementia, to advise a reassessment after six
months or a year. This period of waiting and uncertainty
should be - and patients and their carers clearly tell me
is - stressful and worrying.What recent advances have there been to identify
biomarkers for Alzheimer’s disease?
Considerable progress has been made in the identifica-
tion of biomarkers for AD using molecular markers in
cerebrospinal fluid (CSF) and molecular imaging. Many
groups have contributed to this, but the group of Kaj
Blennow and his colleague Henrik Zetterburg have really
led the field in establishing markers of pathology, includ-
ing the levels of amyloid-beta, which decrease in CSF in
AD, and microtubule-associated protein tau and phosho-
tau levels, which increase in CSF in this condition [3].d. The licensee has exclusive rights to distribute this article, in any medium, for
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markers change over time, their predictive value and
also the current difficulty in reconciling analytical issues
that give variable results in different laboratories. None-
theless, these markers are now in clinical practice in
many parts of the world - certainly in Scandinavia, in-
creasingly in the USA, and also in many countries in
Europe. Molecular imaging is also increasingly used, es-
pecially in clinical trials. The use of positron emission
tomography (PET) ligands for amyloid is well estab-
lished, and Tau ligands are on their way.
The Alzheimer’s Disease Neuroimaging Initiative has
done much to establish the diagnostic and predictive
value of amyloid PET imaging as well as CSF molecular
markers and structural magnetic resonance imaging
(MRI) [4].
In early June 2014, data from the Alzheimer’s Disease
Neuroimaging Initiative and from the European bio-
markers study - AddNeuroMed [5] - were released to-
gether as part of the Sage Bionetworks Dream Challenge
to find biomarkers for AD – an example of crowd-
sourcing solutions to the diagnostic dilemma using
Big Data.What are the prospects for identifying
blood-derived biomarkers for early diagnosis
or prognosis?
My group has long focused on trying to find biomarkers
in blood [6,7]. A decade or so ago, when we started, it
seemed unlikely that such markers would be found. In-
deed, we set off to prove the null hypothesis. However,
we soon found that, by using proteomics, we could iden-
tify a signal - a set of spots on two-dimensional gel elec-
trophoresis and identified by mass spectrometry - and
set out to try and pin this signal down to some mole-
cules for use as biomarkers. We have used proteomics,
genomics, metabolomics and informatics to try to do
this and used these alone, as well as together and with
imaging markers. Many other groups have joined the
search for blood-based biomarkers, reporting some
really interesting results that, like our data, will need
replication.
Along the way, we have learnt three main lessons, but
still have a long way to go. First, we have come to appre-
ciate that samples and data matter. We need many sam-
ples, well curated and with as many data from other
techniques measuring the same analytes as possible. In
fact, we think that no one group can hope to accrue all
the samples necessary for such studies and that the fu-
ture lies with data-aggregation in collaborations such as
the IMI-European Medical Information Framework and
the UK Dementias Platform. Second, we have learnt it
makes no sense to do the conventional case-control
study when we are trying to find markers for occult or
prodromal disease. For this reason, my lab has moved to
an endophenotypic approach. This predicates discovery
on another marker of disease - so, rather than compar-
ing disease cases with healthy controls, we compare or
correlate markers in blood with - variously - rate of de-
cline, structural MRI data, PET amyloid data or CSF
markers of disease. The point is that only some healthy
controls are free from disease and many have the same
amount of disease as the diseased cases. In fact, all of
the people we want to identify with our markers are ac-
tually in the control group. Therefore, this makes no
sense as a study design. Instead, by either disregarding
disease category, or including only people in one cat-
egory, such as mild AD, we can identify markers that
correlate with, and perhaps are surrogates for, actual
pathology. Third, we have found that most ‘omics tech-
nologies remain in their infancy and that no technical
platform is sufficiently superior to others to justify the
enthusiasm sometimes expended on them by their sup-
porters. Having spent the past decade looking for blood
biomarkers, I’m convinced that it isn’t the discussion
around proteomics versus metabolomics, or mass spec-
trometry versus antibody capture that matters, but finding
the best way to utilize elements of all these approaches in
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sensible way forward to me.
Given all this, I think that the evidence suggests that
the prospects for identifying blood-derived markers for
early diagnosis and prognosis are very good [8]. Despite
the somewhat superficial comments one sometimes
hears about ‘fishing expeditions’ and ‘non-replication’,
in fact we are learning some substantial biology and
mechanisms from these studies, and the replication of
some markers across multiple studies is actually rather
impressive [9].
Could blood biomarkers also be used to monitor
the progression of Alzheimer’s disease?
This is less certain. There is very little evidence today
that markers can be used to track disease. However, we
have started a study as part of the UK Dementia Platform,
called the Deep and Frequent Phenotyping study, where
the ‘deep phenotyping’ refers to hugely multimodal assess-
ments, including PET, MRI, electrophysiology, a range of
clinical and cognitive measures and molecular measures
in CSF and blood, and the ‘frequent phenotyping’ refers to
our plans to do much of this multimodal phenotyping re-
peatedly, precisely to identify the marker set most able to
track disease.
Which type of biomarkers do you think would be
more likely to translate into the clinic?
Whether, when and how blood-based biomarkers being
developed in research get translated into the clinic de-
pends somewhat on the data, and somewhat - possibly
a greater somewhat - on health-service-related issues.
These include the ease of requesting and performing the
biomarker test, the cost and also the value to the health
services. So, all the biomarkers under consideration be-
come considerably more valuable, and possibly even indis-
pensable, if a therapy becomes available that is partnered
with a marker. The likelihood of translation is therefore a
combination of acceptability to patients - where blood wins
hands down - to accuracy and utility - where today CSF
measures, possibly, have the edge to ease of use and inter-
pretation - while, from a physician’s perspective, PET
might be a front-runner, where available. In time, the
decision-making is likely to become rationalized around
the evidence, which today is far from complete.
How far are we from using blood-based biomarkers
in the clinic?
Even now, CSF measures are used in clinical practice in
many parts of the world. PET imaging is likely to be
used in some clinical contexts quite soon. Whether
blood-based biomarkers ever get used in the clinic is an
open question. Ten years ago, I would have predicted
that they would never reach the accuracy levels requiredfor clinical utility. Today, as we have just published data
showing an accuracy in prediction of progression from
preclinical syndromes to dementia of around 80%, I am
not so sure [10]. It rather looks to me as though blood-
based biomarkers could be heading to the clinic, perhaps
as part of a suite of diagnostics. Very many more studies
will have to be performed to ascertain test performance
if such tests are to be used in a clinical context and not
just in the research context as we planned. How long
this will take and whether the results in larger and
more-community-based populations will maintain test
outcomes is hard to say. Prediction is always difficult -
especially about the future!
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